This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von der Leyen, H. E. Articles by Dzau, V. J. Search for Related Content PubMed PubMed Citation Articles by von der Leyen, H. E. Articles by Dzau, V. J. Related Collections Gene therapy

(Circulation. 2001;103:2760.)
© 2001 American Heart Association, Inc.

Current Perspective

Therapeutic Potential of Nitric Oxide Synthase Gene Manipulation

Heiko E. von der Leyen, MD; Victor J. Dzau, MD

From the Division of Cardiovascular Research, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Mass (V.J.D.), and Cardion AG, Erkrath, Germany (H.E.v.d.L.).

Correspondence to Victor J. Dzau, Division of Cardiovascular Research, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail vdzau{at}partners.org

Key Words: gene therapy • nitric oxide synthase

	Introduction

Top Introduction Gain of Function: Overexpression... Loss of Function: Inhibition... Potential Therapeutic... References

 
Nitric oxide (NO) plays an important role in many fields of medicine, including immunology, neuroscience, and cardiovascular medicine. NO functions both as a signaling molecule in endothelial and nerve cells and as a killer molecule for activated immune cells. Its ubiquitous distribution in the body and its multiple roles have influenced our understanding of how cells communicate and function.¹ Cloning and characterization of the different isoforms of NO synthase (NOS) paved the way for a better understanding of the regulation of NO pathways and for the development of therapeutic gene transfer.^{2 3} Three isoforms of NOS have been described: constitutive-type isoforms like neuronal NOS (NOS I) and endothelial cell NOS (eNOS; NOS III), and the inducible type of the enzyme (inducible NOS [iNOS; NOS II]). The constitutive isoforms are calcium-dependent and regulated (eg, by shear stress); the inducible isoform can be rapidly induced by cytokines to produce high amounts of NO.² With the recent availability of efficient transduction systems for in vivo gene transfer, as well as other methods of gene manipulation, the time is ripe to consider NOS gene therapy.⁴ This article will focus on potentially feasible approaches of the manipulation of the NOS gene(s) using DNA expression vectors or antisense oligonucleotides designed to enhance or modify NOS activity for clinical therapeutic benefit.

NO mediates vasorelaxation, inhibits vascular smooth muscle cell (VSMC) migration and proliferation, attenuates platelet activation and adhesion, and reduces vascular inflammation.¹ In patients with cardiovascular risk factors such as hypertension, hypercholesterolemia, smoking, or diabetes, endothelium-dependent relaxation is impaired, demonstrating reduced NO bioactivity.⁵ In atherosclerosis, restenosis, transplant vasculopathy, and bypass graft disease, the levels of NO activity are consistently reduced. This decline is due to increased catabolism and/or decreased production of NO, depending on the stage of atherosclerosis and the type of vascular disease. When eNOS expression is measured directly, it is elevated early in the development of (experimental) atherosclerosis.⁶ However, the concomitant increased oxidative stress inactivates NO and forms the toxic end product peroxynitrite.⁷ In more established human atherosclerotic plaque, direct measurements revealed reduced eNOS expression and NO release.⁸ Low levels of essential cofactors like tetrahydrobiopterin (BH₄) in vascular pathological conditions may be the cause of the adverse action of eNOS in contributing to oxygen-derived free radical formation.⁹ Specific mechanisms by which cholesterol and reactive oxygen species regulate caveolae formation, eNOS expression, and eNOS-caveolin interactions may further modulate endothelial function.¹⁰ A delicate balance in the interaction of NO with physiological cofactors and pathophysiological mediators may determine whether NO is beneficial or detrimental for local vascular function, eg, by terminating the autocatalytic chain of lipid peroxidation (initiated by oxidized LDL).¹¹ The dysregulation of cell growth, cell death, cell migration, inflammation, and extracellular matrix, which are associated with impaired NO activity in the vessel wall, lead to pathological vascular remodeling. Dysfunctional activity of eNOS may also be the result of mutations of the eNOS gene; this was demonstrated in patients with severe coronary vasospasm in the absence of clinically relevant stenoses and in eNOS-knockout mice.^{12 13}

	Gain of Function: Overexpression of NOS Gene

Top Introduction Gain of Function: Overexpression... Loss of Function: Inhibition... Potential Therapeutic... References

 
Treatment of Disorders of Pathological Vascular Remodeling
Experimental evidence from pharmacological and gene transfer studies suggests that NO inhibits VSMC proliferation.¹⁴ The imbalance of physiological mediators creates unique opportunities for NOS gene transfer. Restoring the beneficial effects of NO activity ("gain of function") may provide potential therapeutic benefit for the treatment of several forms of cardiovascular disease (Table 1).

View this table: [in this window] [in a new window]   Table 1. Genetic Engineering Approaches to Study NO

The overexpression of eNOS in balloon-injured rat carotid arteries using fusigenic liposomes¹⁵ not only restored NO production within the vessel wall, but also significantly improved the vascular reactivity of the vessel.¹⁶ Furthermore, eNOS transgene expression resulted in a 70% inhibition of neointima formation. Since this initial report demonstrating functional biological activity of a transfected recombinant DNA vector,¹⁶ several other groups have confirmed the salutary effects of NOS gene transfer on various experimental models of vascular disease (Table 2). Transfer of an adenoviral vector encoding human eNOS to balloon-injured rat carotid arteries resulted in increased local NO production and restoration of cGMP levels to those observed in uninjured vessels and in a 70% reduction of the neointimal surface area induced by balloon injury.¹⁷ Using an interventional drug delivery device (Infiltrator, IVT), the same group reported successful NOS gene transfer to injured porcine left anterior descending coronary arteries.¹⁸ In this model of intracoronary gene transfer, overexpressing eNOS resulted in significant inhibition of neointimal lesion formation. In transgenic animals lacking eNOS (eNOS^–/– knockout), luminal remodeling was impaired in response to reduced flow due to ligation, and vessel wall thickness doubled due to proliferation of VSMCs.¹⁹ In a rabbit model of atherosclerosis, the overexpression of neuronal NOS (a constitutive NOS isoform) rapidly ameliorated several markers of atherosclerosis.²⁰ Thus, these data support the recognition of NO as a major determinant of the vessel wall architecture responsible for vascular remodeling.

View this table: [in this window] [in a new window]   Table 2. NOS Gene Transfer in Various Experimental Models Demonstrating Inhibition of Vascular Lesion Formation

Recently, it was demonstrated that NO inhibits the migration of mitogen-stimulated VSMCs in vitro.²¹ Tyrosine phosphorylation of paxillin may be one mechanism resulting in mitogen-induced VSMC migration. The transfer of an eNOS adenoviral vector in VSMCs inhibited the platelet-derived growth factor-BB–induced tyrosine phosphorylation of paxillin.²² In addition, tyrosine phosphorylation of focal adhesion kinase (FAK) was inhibited. Considering the importance of FAK and paxillin in cell migration and proliferation, the FAK-paxillin pathway may represent an important target for NO action to inhibit VSMC migration and proliferation.

Overexpressing iNOS has also been used successfully to inhibit experimental vascular lesion formation (Table 2), and it has been recognized as a autoregulatory feedback inhibitor of vascular inflammation.²³ Transferring the human iNOS gene using a retroviral vector resulted in significant protein expression in endothelial cells or VSMCs in vitro and prevented neointimal lesion formation in porcine arteries after balloon injury.²⁴ In a more advanced model of vascular injury (stent-induced intimal proliferation), we showed in porcine peripheral and coronary arteries that, using the infiltrator device, liposome-mediated gene transfer of iNOS inhibited stent-induced lesion formation by 40% to 50%.²⁵

There is increasing evidence that NO may prevent intimal hyperplasia by protecting the endothelium. In cultured sheep arterial endothelial cells, transfection of an iNOS-adenoviral vector did not affect the viability of the endothelial cells. The prolonged exposure to NO did not induce the apoptosis of endothelial cells; instead, it inhibited lipopolysaccharide-induced apoptosis by reducing caspase-3-like protease activity.²⁶ In vitro experiments support a protective effect of NO on endothelial cells exposed to superoxide radicals.²⁷ iNOS gene transfer reduced oxygen radical production in vitro, thereby potentially inhibiting the adhesion of monocytes to vascular endothelium,²⁸ as was demonstrated previously with NO donors.^{27 29}

Saphenous veins are used frequently as arterial bypass grafts (eg, for aortocoronary bypass). These grafts fail at a rate of 10% to 30% annually due to thrombosis, neointimal hyperplasia, and accelerated atherosclerosis. In humans, the saphenous vein has a very low expression and function of the L-arginine/NO pathway.³⁰ Cable et al³¹ transduced human saphenous veins with an adenovirus vector encoding bovine eNOS and demonstrated functional expression of the recombinant NOS. This approach may provide a genetic engineering tool to reduce the risk of early thrombosis and later accelerated atherosclerosis in saphenous vein grafts by providing increased vascular NO production.

Alloimmune response in the rat aortic allograft model with subsequent endothelial dysfunction and injury results in the exposure of the underlying VSMCs to mitogenic factors, with subsequent neointimal lesion formation.³² Gene transfer of an adenoviral vector encoding iNOS in the aortic grafts effectively inhibited intimal hyperplasia in both the presence and absence of cyclosporin A.³³ iNOS^–/– knockout mice experienced a significant increase in the severity and frequency of intimal thickening in response to alloimmune injury in a heterotopic cardiac transplant model.³⁴ Thus, iNOS may play a vascular protective role, suggesting a therapeutic benefit of iNOS gene transfer as an endogenous physiological repair mechanism.

Taken together, these data demonstrate that the in vivo gene transfer of either eNOS or iNOS, regardless of the species of origin, can consistently inhibit the development of a wide range of experimental vascular diseases, including restenosis, atherosclerosis, vein graft disease, and transplant vasculopathy. We think that NOS gene therapy may be an effective treatment strategy for diseases involving pathological vascular remodeling.

Many intriguing issues should be resolved while approaching the application of NOS gene therapy for human diseases. First, why use NOS gene therapy rather than NO donors or NO adducts?³⁵ We think that NOS gene transfer enables the achievement of therapeutic concentrations of NO locally in the target tissue, without the potential adverse effects of the excessively high blood levels that occur when using systemic therapy. Second, which is more effective and/or safe: eNOS or iNOS? To date, data suggest both are effective and safe. It is surprising that iNOS gene transfer is not associated with the cytotoxicity observed with the activation of the endogenous gene.^{25 26 33} Furthermore, a recent study showed that periadventitial expression of iNOS counteracted the progression of intimal thickening in a rabbit carotid artery balloon injury model.³⁶ This observation of the efficacy of iNOS gene therapy in experimental vascular disease may be related (1) to a lower level of NO achieved with exogenous gene transfer compared with endogenous gene activation, (2) to the intracellular distribution of NO as the result of the expression of exogenous gene construct versus endogenous native gene, and/or (3) to the microenvironment of the iNOS gene product accumulation (eg, the level of BH₄). The higher turnover rate of iNOS may be preferable for clinical use because low concentrations could be used, thereby minimizing the risk of systemic distribution of relevant amounts of DNA vector.

In NIH 3T3 cells constitutively expressing recombinant human iNOS, subunits of this isoform dimerize to form an active enzyme; BH₄ seems to play a critical role in promoting this process.³⁷ A human expression plasmid encoding GTP cyclohydrolase I, the rate-limiting enzyme for BH₄ biosynthesis, was successfully cotransfected with iNOS into VSMCs to reconstitute iNOS activity.³⁸ Thus, GTP cyclohydrolase I gene transfer could be used to provide a cofactor to targeted cells, even if it was synthesized in neighboring cells; thus, this substance may augment the production of NO after iNOS gene transfer. It has been demonstrated that blood vessels depleted of BH₄ produce hydrogen oxide.⁹ Furthermore, the reduced superoxide formation that occurs after adding BH₄ to calcium/calmodulin-stimulated recombinant eNOS in the presence of L-arginine³⁹ supports the view that BH₄ may have a critical role in influencing eNOS-mediated superoxide quenching.

An important point for consideration in NOS gene therapy is the desirable duration of transgene expression. In the case of restenosis, transient expression of sufficient duration to inhibit the surge of mitogen activation and VSMC proliferation may be all that is needed to achieve a therapeutic effect. However, to prevent atherosclerosis, stable chromosomal integration of the transgene with long-term, regulable expression in a cell-specific manner may be required.

Overexpression of NOS Gene for Treatment of Vasospastic Disorders
We¹⁶ and others⁴⁰ showed a diminished contractile response and enhanced endothelium-dependent relaxation at day 4 after in vivo gene transfer of an eNOS vector in rat or rabbit carotid arteries. In an ex vivo study, an eNOS adenoviral vector was successfully transferred to large canine cerebral arteries.⁴¹ Functional expression of eNOS resulted in increased basal production of cGMP, with a subsequent reduction in receptor-mediated contractile response and an enhancement of endothelium-derived relaxation. The retrovirus-mediated overexpression of human eNOS in rat VSMCs in culture with subsequent in vivo seeding of these transformed cells into denuded rat carotid arteries induced marked dilatation of the vessel at 2 weeks after seeding.⁴² Perivascular vector application via cerebrospinal fluid resulted in the expression of recombinant eNOS in cerebral arteries, thus demonstrating a potentially feasible therapeutic approach to alleviate cerebral vasospastic conditions.⁴¹ The incubation of rabbit carotid arteries⁴³ or porcine coronary arteries⁴⁴ in organ culture with an eNOS adenoviral vector augmented vasorelaxation in response to stimuli that release NO. Gene transfer in organ culture resulted in eNOS transgene expression preferentially in adventitial cells, suggesting that adventitial gene transfer may be sufficient to alter vasomotor tone.⁴³ In summary, these data underline the potential role of eNOS gene transfer in our therapeutic arsenal for the treatment of vasospasm and endothelial dysfunction.

Pulmonary gene transfer with delivery of recombinant eNOS adenovirus by a single aerosolization enabled diffuse transduction of bronchial and alveolar epithelial cells, as well as vascular adventitial and endothelial cells, with subsequent increased NO production.⁴⁵ During acute hypoxia, this local overexpression of eNOS in rat lungs significantly influenced pulmonary artery pressure and total pulmonary resistance without affecting systemic hemodynamics. Thus, aerosolized eNOS gene transfer can act as a selective pulmonary vasodilator; this represents an attractive therapeutic approach to treat patients with pulmonary hypertension and extends the already established therapeutic application of NO inhalation.⁴⁶

	Loss of Function: Inhibition of NOS by Antisense Technology

Top Introduction Gain of Function: Overexpression... Loss of Function: Inhibition... Potential Therapeutic... References

 
Targeting NOS by a "loss of function" approach is aimed at inhibiting the expression of specific NOS isoform gene(s) using antisense technology (Table 1). Oxidant stress may be accompanied by the enhanced expression of endogenous iNOS, markedly increased production of intracellular NO, and/or impaired cell viability in some cell systems.⁴⁷ With the identification of a hypoxia-responsive element on the iNOS gene, a novel and alternate pathway for the activation of the iNOS gene was discovered.⁴⁸ In ceropithecus monkey kidney tubular epithelial cells (BSC-1), selective inhibition of iNOS using phosphorothioate-modified antisense oligonucleotides dramatically improved BSC-1 cell viability after oxidant stress.⁴⁹ By inhibiting the hydrogen peroxide–induced NO release, epithelial cells were rescued by reducing the detrimental effect of NO or NO-related superoxide radicals. In rats subjected to renal ischemia and concomitant hypoxia-induced oxidant stress, acute renal failure was attenuated by antisense oligonucleotides directed against iNOS, providing direct evidence for a cytotoxic effect of iNOS in this model of ischemic renal failure.⁵⁰ The nature of the interaction of NO and superoxide radicals and the subsequent pathophysiological consequences are still a matter of controversy.^{51 52} Because of differences in species, tissues, and pathophysiological models, NO may either scavenge superoxide radicals or actually increase the cellular oxidant stress. These effects of NO are probably dose-dependent, such that massive NO formation may be toxic, but lower, more physiological levels of NO may be protective. In addition, the source of NO and the relationship between NO and tissue injury⁵³ are important issues that need to be addressed in future research.

Differences in the pathophysiological role of NO in different cell types may be explained by tissue-specific transcriptional regulation of the iNOS promoter/enhancer, as was reported recently in VSMCs and macrophages.⁵⁴ Cartwright et al⁵⁵ generated a murine macrophage cell line expressing a 500-base pair (bp) sequence of iNOS in either the antisense or sense orientation, driven by the SV40 promoter/enhancer region. Adhesion of the antisense-treated cell line A10 to cytokine-stimulated murine endothelial cells was significantly higher than that of the sense-treated cell lines. There was a negative correlation between the amount of NO produced and the level of adhesion, thus indicating an antiadhesive role for NO.

Antisense oligonucleotides to iNOS may be used to treat sepsis. In a recent study of cultured rat pulmonary artery VSMCs, the NOS gene was induced in response to lipopolysaccharides and cytokines. Preincubation of the cells in the presence of an antisense oligonucleotide to the first 18 bases after the initiation codon of iNOS mRNA caused an significant decrease in cytokine-induced NO₂ production in a concentration-dependent manner.⁵⁶ Excessive NO production brought about by cytokine stimulation in septic shock contributes to hemodynamic instability and perhaps to tissue leak. Thus, NOS inhibition in this pathophysiological context may confer treatment benefit on clinical septic shock.⁵⁷

	Potential Therapeutic Applications of NOS Gene Transfer

Top Introduction Gain of Function: Overexpression... Loss of Function: Inhibition... Potential Therapeutic... References

 
Potential applications for in vivo gene therapy using NOS overexpression or inhibition may cover a broad range of vascular or inflammatory disorders (Table 3). However, there are still unresolved issues concerning the efficacy and safety of NOS gene therapy, the selection of iNOS versus eNOS, and the duration of transgene expression that remain to be addressed. Given that the activation of mitogenic factors mediating the cellular processes essential for vascular lesion formation occurs within the first few days after angioplasty and stenting, the short-term expression of NOS transgene during the early period after injury may be critical and sufficient to prevent the subsequent development of restenosis.^{16 17} Thus, it is possible to consider designing and conducting clinical trials of NOS gene therapy for human restenosis in the near future, contingent on the documentation of a safe and efficient gene delivery method. However, NOS gene therapy for chronic human vascular disease will require more extensive research and the development of long-term, stable, regulable, and cell-specific expression systems. Obviously, these systems must be proven to be efficient and safe for human use.

View this table: [in this window] [in a new window]   Table 3. Potential Clinical Applications of NOS Gene Transfer

NOS gene therapy provides a unique opportunity for cardiovascular treatment. In contrast to therapies using transgenes with exclusive intracellular action (eg, suicide genes such as thymidine kinase), diffusible NO (the product of NOS gene therapy) enhances the therapeutic potential via its paracrine actions and thus renders this approach less dependent on transfection efficiency of the transgene into the target cells.

Gene therapy for cardiovascular disease is now entering the stage of clinical evaluation. Patient safety must be the first and foremost consideration in human gene therapy when entering the stage of clinical trials to assess feasibility and efficacy of NOS gene therapy.

Note Added in Proof
The US Food and Drug Administration and the Recombinant Advisory Committee at the National Institutes of Health recently approved a Phase I NOS gene transfer study, which will be launched in spring of 2001.

	Acknowledgments

 
Dr von der Leyen is supported by grants from the Deutsche Forschungsgemeinschaft (Le 567/3-1, 3-2, 6/1) and the ADUMED Foundation, Zürich, Switzerland. Dr Dzau is the recipient of an NIH MERIT Award (HL 35610). The study was supported in part by NIH grants HL-35610 and HL-58516.

	Footnotes

 
Dr von der Leyen is Medical Director of and Dr Dzau is a consultant for Cardion AG, which has an active program in NOS gene therapy.

	References

Top Introduction Gain of Function: Overexpression... Loss of Function: Inhibition... Potential Therapeutic... References

 
1. Schmidt HHHW, Walter U. NO at work. Cell. 1994;78:919–925.[Medline] [Order article via Infotrieve]

2. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915–918.[Medline] [Order article via Infotrieve]

3. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res. 1999;43:509–520.[Abstract/Free Full Text]

4. von der Leyen H, Mann MJ, Dzau VJ. Gene therapy of cardiovascular disorders. In: Alexander RW, Schlant RC, Fuster V, eds. Hurst’s The Heart. 9th ed. New York, NY: McGraw-Hill Publishing Co; 1998:213–225.

5. Dzau VJ. Atherosclerosis and hypertension: mechanisms and interrelationships. J Cardiovasc Pharmacol. 1990;15:S59–S64.

6. Minor R, Myers PR, Guerra R, et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990;86:2109–2116.

7. Ohara Y, Peterson TE, Harrison DG. Hypercholsterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551.

8. Oemar BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494–2498.[Abstract/Free Full Text]

9. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41–46.[Medline] [Order article via Infotrieve]

10. Peterson TE, Poppa V, Ueba H, et al. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res. 1999;85:29–37.[Abstract/Free Full Text]

11. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol. 1996;7:274–280.[Medline] [Order article via Infotrieve]

12. Nakayama M, Yasue H, Yoshimura M, et al. A T-786 -C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999;99:2864–2870.[Abstract/Free Full Text]

13. Gödecke A, Decking UKM, Ding Z, et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circulation. 1998;82:186–194.

14. Jeremy JY, Rowe D, Emsley AM, et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999;43:580–594.[Free Full Text]

15. Mann MJ, Morishita R, Gibbons GH, et al. DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HVJ)-liposomes. Mol Cell Biochem. 1997;172:3–12.[Medline] [Order article via Infotrieve]

16. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial-cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137–1141.[Abstract/Free Full Text]

17. Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97:1274–1281.[Abstract/Free Full Text]

18. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 1998;98:919–926.[Abstract/Free Full Text]

19. Rudic RD, Shesely EG, Maeda N, et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101:731–736.[Medline] [Order article via Infotrieve]

20. Qian H, Neplioueva V, Shetty GA, et al. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99:2979–2982.[Abstract/Free Full Text]

21. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest. 1995;96:141–149.

22. Fang S, Sharma RV, Bhalla RC. Endothelial nitric oxide synthase gene transfer inhibits platelet-derived growth factor-BB stimulated focal adhesion kinase and paxillin phosphorylation in vascular smooth muscle. Biochem Biophys Res Commun. 1997;236:706–711.[Medline] [Order article via Infotrieve]

23. Peng HB, Spiecker M, Liao JK. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol. 1998;161:1970–1976.[Abstract/Free Full Text]

24. Tzeng E, Shears LL, Robins PD, et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med. 1996;2:211–225.[Medline] [Order article via Infotrieve]

25. von der Leyen HE, Muhs A, Schrader J, et al. Inhibition of in-stent plaque formation by inducible nitric oxide synthase-lipoplex-mediated gene therapy in a pig femoral artery stent model. J Am Coll Cardiol. 2000;35(suppl A):280A. Abstract.

26. Tzeng E, Kim YM, Pitt BR, et al. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery. 1997;122:255–263.[Medline] [Order article via Infotrieve]

27. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 1997;96:934–940.[Abstract/Free Full Text]

28. Buitrago R, von der Leyen H, Tsao PS, et al. Superoxide generation from endothelial cells exposed to oxidized LDL can be reduced by nitric oxide synthase gene transfer in vitro. Circulation. 1995;92:I-364. Abstract.

29. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60–68.

30. Yang ZH, von Segesser L, Bauer E, et al. Different activation of endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res. 1991;68:52–60.[Abstract/Free Full Text]

31. Cable DG, O’Brien T, Schaff HV, et al. Recombinant endothelial nitric oxide synthase-transduced human saphenous veins: gene therapy to augment nitric oxide production in bypass conduits. Circulation. 1997;96:II-173–II-178.

32. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation. 1996;93:457–462.[Abstract/Free Full Text]

33. Shears LL, Kawaharada N, Tzeng E, et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 1997;100:2035–2042.[Medline] [Order article via Infotrieve]

34. Koglin J, Glysing-Jensen T, Mudgett JS, et al. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation. 1998;97:2059–2065.[Abstract/Free Full Text]

35. Nathan C. Inducible nitric oxide synthases: what differences does it make? J Clin Invest. 1997;100:2417–2423.[Medline] [Order article via Infotrieve]

36. De Meyer GRY, Kockx MM, Cromheeke KM, et al. Periadventitial inducible nitric oxide synthase expression and intimal thickening. Arterioscl Thromb Vasc Biol. 2000;20:1896–1902.[Abstract/Free Full Text]

37. Tzeng E, Billiar TR, Robbins PD, et al. Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A. 1995;92:11771–11775.[Abstract/Free Full Text]

38. Tzeng E, Yoneyama T, Hatakeyama K, et al. Vascular inducible nitric oxide synthase gene therapy: requirement for guanosine triphosphate cyclohydrolase I. Surgery. 1996;120:315–321.[Medline] [Order article via Infotrieve]

39. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998;95:9220–9225.[Abstract/Free Full Text]

40. Kullo IJ, Mozes G, Schwartz RS, et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation. 1997;96:2254–2261.[Abstract/Free Full Text]

41. Chen AFY, O’Brien T, Tsutsui M, et al. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery. Circ Res. 1997;80:327–335.[Abstract/Free Full Text]

42. Chen L, Daum G, Forough R, et al. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res. 1998;82:862–870.[Abstract/Free Full Text]

43. Ooboshi H, Chu Y, Rios CD, et al. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. Am J Physiol. 1997;273:H265–H270.[Abstract/Free Full Text]

44. Cable DG, O’Brien T, Kullo IJ, et al. Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. Cardiovasc Res. 1997;35:553–559.[Abstract/Free Full Text]

45. Janssens SP, Bloch KD, Nong Z, et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest. 1996;98:317–324.[Medline] [Order article via Infotrieve]

46. Pepke-Zaba J, Higgenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173–1174.[Medline] [Order article via Infotrieve]

47. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620–1624.[Abstract/Free Full Text]

48. Melillo G, Musso T, Sica A, et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med. 1995;182:1683–1693.[Abstract/Free Full Text]

49. Peresleni T, Noiri E, Bahou WF, et al. Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Am J Physiol. 1996;270:F971–F977.[Abstract/Free Full Text]

50. Noiri E, Peresleni T, Miller F, et al. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest. 1996;97:2377–2383.[Medline] [Order article via Infotrieve]

51. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell. 1994;78:931–936.[Medline] [Order article via Infotrieve]

52. Takano H, Manchikalapudi S, Tang X, et al. Nitric oxide synthase is the mediator of late preconditioning agaist myocardial infarction in conscious rabbits. Circulation. 1998;98:441–449.[Abstract/Free Full Text]

53. Tzeng E, Billiar TR. Nitric oxide and the surgical patient. Arch Surg. 1997;132:977–982.[Abstract/Free Full Text]

54. Kolyada AY, Savikovsky N, Madias NE. Transcriptional regulation of the human iNOS gene in vascular-smooth-muscle cells and macrophages: evidence for tissue specificity. Biochem Biophys Res Commun. 1996;220:600–605.[Medline] [Order article via Infotrieve]

55. Cartwright JE, Johnstone AP, Whitley GSJ. Inhibition of nitric oxide synthase by antisense techniques: investigations of the roles of NO produced by murine macrophages. Br J Pharmacol. 1997;120:146–152.[Medline] [Order article via Infotrieve]

56. Thomae KR, Geller DA, Billiar TR, et al. Antisense oligodeoxynucleotide to inducible nitric oxided synthase inhibits nitric oxide synthesis in rat pulmonary artery smooth muscle cells in culture. Surgery. 1993;114:272–277.[Medline] [Order article via Infotrieve]

57. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557–1558.[Medline] [Order article via Infotrieve]

58. Shears LL, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs. J Am Coll Surg. 1998;187:295–306.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				M. M. Cortese-Krott, C. V. Suschek, W. Wetzel, K.-D. Kroncke, and V. Kolb-Bachofen Nitric oxide-mediated protection of endothelial cells from hydrogen peroxide is mediated by intracellular zinc and glutathione Am J Physiol Cell Physiol, April 1, 2009; 296(4): C811 - C820. [Abstract] [Full Text] [PDF]

				H. Suzuki, K. Kimura, H. Shirai, K. Eguchi, S. Higuchi, A. Hinoki, K. Ishimaru, E. Brailoiu, D. N. Dhanasekaran, L. N. Stemmle, et al. Endothelial Nitric Oxide Synthase Inhibits G12/13 and Rho-Kinase Activated by the Angiotensin II Type-1 Receptor: Implication in Vascular Migration Arterioscler. Thromb. Vasc. Biol., February 1, 2009; 29(2): 217 - 224. [Abstract] [Full Text] [PDF]

				H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor Endocrinology, December 1, 2006; 147(12): 5914 - 5920. [Abstract] [Full Text] [PDF]

				L. Liu, H. Liu, G. Visner, and B. S. Fletcher Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats FASEB J, December 1, 2006; 20(14): 2594 - 2596. [Abstract] [Full Text] [PDF]

				S Moncada Adventures in vascular biology: a tale of two mediators Phil Trans R Soc B, May 29, 2006; 361(1469): 735 - 759. [Abstract] [Full Text] [PDF]

				S. Nakata, M. Tsutsui, H. Shimokawa, M. Tamura, H. Tasaki, T. Morishita, O. Suda, S. Ueno, Y. Toyohira, Y. Nakashima, et al. Vascular Neuronal NO Synthase Is Selectively Upregulated by Platelet-Derived Growth Factor: Involvement of the MEK/ERK Pathway Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2502 - 2508. [Abstract] [Full Text] [PDF]

				L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1761 - 1774. [Abstract] [Full Text] [PDF]

				L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]

				T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]

				Z. S. Katusic, N. M. Caplice, and K. A. Nath Nitric Oxide Synthase Gene Transfer as a Tool to Study Biology of Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1990 - 1994. [Abstract] [Full Text] [PDF]

				C. V. Suschek, O. Schnorr, K. Hemmrich, O. Aust, L.-O. Klotz, H. Sies, and V. Kolb-Bachofen Critical Role of l-Arginine in Endothelial Cell Survival During Oxidative Stress Circulation, May 27, 2003; 107(20): 2607 - 2614. [Abstract] [Full Text] [PDF]

				T. H. Kim, K. A. Skelding, E. G. Nabel, and R. D. Simari What can cardiovascular gene transfer learn from genomics: and vice versa? Physiol Genomics, December 3, 2002; 11(3): 179 - 182. [Abstract] [Full Text] [PDF]

				D. Eguchi, L. V. d'Uscio, C. Wambi, D. Weiler, I. Kovesdi, T. O'Brien, and Z. S. Katusic Inhibitory effect of recombinant iNOS gene expression on vasomotor function of canine basilar artery Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2560 - H2566. [Abstract] [Full Text] [PDF]

				Z. S. Katusic Therapeutic Angiogenesis: New Indication for Endothelial NO Synthase Gene Transfer Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1254 - 1255. [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von der Leyen, H. E. Articles by Dzau, V. J. Search for Related Content PubMed PubMed Citation Articles by von der Leyen, H. E. Articles by Dzau, V. J. Related Collections Gene therapy